The biotechnology company Theratechnologies has announced a major shortage of its drug Egrifta (tesamorelin, for injection), which reduces HIV-related excess belly fat. The depleted stocks are a consequence, the company says, of “manufacturing delays and issues observed during the production of new batches of Egrifta.”

Consequently, the company has temporarily halted production of the drug. No estimates have been released as to when Egrifta manufacturing will be back underway. The company has stated that it is conducting an investigation as to the cause of this kerfuffle.

To read a press release about the shortage, click here.